A new prognostic model for localized renal cell carcinoma
SB: idea, manuscript writing/editing
Compliance with ethical standards
Conflict of interest
S. Buti received honoraria for advisory role and as speaker at scientific events from Pfizer, BMS, IPSEN, Pierre-Fabre, Merck Sharp & Dohme (MSD), AstraZeneca; he also received research funding from Novartis.
- 2.Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB (2017) Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 28:2747–2753. https://doi.org/10.1093/annonc/mdx492 CrossRefGoogle Scholar
- 3.Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466–472CrossRefGoogle Scholar
- 4.Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E, Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C, POLAR-01 Trial Investigators (2014) Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC). J Immunother 37:440–447. https://doi.org/10.1097/CJI.0000000000000055 CrossRefGoogle Scholar